Cellectis (NASDAQ:CLLS) Share Price Passes Above 50 Day Moving Average - Here's Why

Key Points

• Cellectis S.A. stock price recently crossed above its fifty-day moving average, trading at $2.57, an increase from its average of $2.25.
• Several analysts have issued mixed ratings for Cellectis, with Barclays lowering its price target to $4.00 and a consensus rating of "Buy."
• The company reported a revenue of $18.19 million for the last quarter, significantly exceeding analyst expectations, despite a negative earnings per share of ($0.24).

Shares of Cellectis S.A. (NASDAQ:CLLS - Get Free Report) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.25 and traded as high as $2.68. Cellectis shares last traded at $2.57, with a volume of 35,096 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently commented on CLLS shares. Barclays decreased their target price on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Wall Street Zen cut Cellectis from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $4.00.

Cellectis Stock Down 0.8%

The company has a debt-to-equity ratio of 0.58, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a market cap of $142.84 million, a PE ratio of -3.13 and a beta of 3.03. The business has a fifty day moving average price of $2.31 and a two-hundred day moving average price of $1.72.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. The business had revenue of $18.19 million for the quarter, compared to analysts' expectations of $10.07 million. On average, analysts anticipate that Cellectis S.A. will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. OLD Mission Capital LLC purchased a new position in Cellectis in the first quarter valued at about $31,000. Wells Fargo & Company MN grew its stake in Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Acadian Asset Management LLC grew its stake in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 26,461 shares in the last quarter. Millennium Management LLC purchased a new position in Cellectis in the fourth quarter valued at about $962,000. Finally, Long Focus Capital Management LLC grew its stake in Cellectis by 2.2% in the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.